TY - JOUR T1 - ▼Etanercept and ▼infliximab for rheumatoid arthritis JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 49 LP - 52 DO - 10.1136/dtb.2001.39749 VL - 39 IS - 7 A2 - , Y1 - 2001/07/01 UR - http://dtb.bmj.com/content/39/7/49.abstract N2 - Relevant BNF section: 10.1.3&#9660Etanercept* (Enbrel - Wyeth) and&#9660infliximab* (Remicade - Schering Plough) belong to a new class of drugs that block the effects of tumour necrosis factor-alpha (TNF-α), a mediator of inflammation. Both are licensed for the treatment of patients with active rheumatoid arthritis who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs). Here, we consider whether etanercept and infliximab offer advantages. ER -